Related Experiment Videos
Minimal residual disease in soft-tissue sarcomas
1Department of Surgery, Klinikum Mannheim gGmbH, University of Heidelberg, Mannheim, Germany. frank.willeke@chir.ma.uni-heidelberg.de
Abstract:
Soft-tissue sarcomas are characterized by the development of disease recurrence in a distinct subgroup of patients. Despite intense efforts in applying multimodal treatment, the risk of local recurrence or distant metastases remains a considerable threat to patients with soft-tissue sarcoma. This review focuses on the efforts aimed at defining local and systemic tumor extent at the level of minimal residual disease (MRD) tumor cell detection. Examination of MRD in soft-tissue sarcomas has experienced a significant boost from the definition of fusion transcripts resulting from stable chromosomal translocations. The sensitivity and exclusive specificity of the reverse-transcription polymerase chain reaction (RT-PCR) protocols have given insights into tumor cell residues in nearly all body compartments. The accumulated data demonstrates that even after oncologic resections most patients will still harbor a significant tumor burden. Clinical concepts arising out of these new data are under way. One of these concepts is the targeting of the fusion transcript for therapy. However, this approach is still restricted to the experimental setting. The development of clinical applications remains a challenging task, requiring the treatment of as many patients as possible in centers specializing in all of the affected disciplines.
Insights
Detecting minimal residual disease (MRD) in soft-tissue sarcoma using fusion transcripts via RT-PCR reveals significant tumor burden post-resection. This finding prompts new therapeutic strategies targeting these transcripts.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Soft-tissue sarcomas frequently recur despite multimodal treatment.
- Local recurrence and distant metastases remain significant threats to patient outcomes.
- Defining the extent of minimal residual disease (MRD) is crucial for managing recurrence risk.
Purpose of the Study:
- To review advancements in detecting minimal residual disease (MRD) in soft-tissue sarcomas.
- To explore the role of fusion transcripts and RT-PCR in identifying residual tumor cells.
- To discuss the implications of MRD detection for future therapeutic strategies.
Main Methods:
- Focus on the detection of minimal residual disease (MRD) in soft-tissue sarcomas.
- Utilizing fusion transcripts derived from chromosomal translocations as biomarkers.
- Employing highly sensitive and specific reverse-transcription polymerase chain reaction (RT-PCR) protocols.
Main Results:
- Fusion transcript detection has significantly advanced MRD assessment in soft-tissue sarcomas.
- RT-PCR reveals tumor cell residues in various body compartments, even after resection.
- A substantial tumor burden often persists in patients post-oncologic surgery.
Conclusions:
- MRD detection using fusion transcripts provides critical insights into residual disease in soft-tissue sarcoma.
- Targeting fusion transcripts for therapy is an emerging, albeit experimental, strategy.
- Clinical application requires multidisciplinary expertise and extensive patient data from specialized centers.